Percutaneous closure of patent foramen ovale
DOI:
https://doi.org/10.6016/ZdravVestn.3153Keywords:
cryptogenic ischemic stroke, embolic stroke of undetermined origin, patent foramen ovale, atrial fibrillation, hypercoagulable stateAbstract
Patent foramen ovale (PFO) is a remnant of an embryological atrial communication, which normally closes spontaneously after birth. However, it remains open in 25% of the general population. It is linked to several conditions due to a right-left shunt, including cryptogenic ischemic stroke, systemic embolism, migraine, and decompression illness. Percutaneous PFO closure is a relatively simple and safe procedure, which has been indicated in selected patients. Results from relevant studies show that closure is reasonable in younger patients with embolic ischemic stroke, where after thorough and comprehensive diagnostics and exclusion of alternative causes, the cause still remains undetermined. Even after percutaneous closure of PFO, lifelong secondary medical treatment is mandatory. To date, the results of the studies show that percutaneous closure is not indicated in the treatment of migraine, but is indicated in active and professional divers after decompression illness. Patients with an indication for percutaneous PFO closure should be referred to a multidisciplinary PFO council.
Downloads
References
1. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59(1):17-20.
DOI: 10.1016/S0025-6196(12)60336-X
PMID: 6694427
2. Hara H, Virmani R, Ladich E, Mackey-Bojack S, Titus J, Reisman M, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol. 2005;46(9):1768-76.
DOI: 10.1016/j.jacc.2005.08.038
PMID: 16256883
3. Calvert PA, Rana BS, Kydd AC, Shapiro LM. Patent foramen ovale: anatomy, outcomes, and closure. Nat Rev Cardiol. 2011;8(3):148-60.
DOI: 10.1038/nrcardio.2010.224
PMID: 21283148
4. Horton SC, Bunch TJ. Patent foramen ovale and stroke. Mayo Clin Proc. 2004;79(1):79-88.
DOI: 10.4065/79.1.79
PMID: 14708951
5. Mattle HP, Meier B, Nedeltchev K. Prevention of stroke in patients with patent foramen ovale. Int J Stroke. 2010;5(2):92-102.
DOI: 10.1111/j.1747-4949.2010.00413.x
PMID: 20446943
6. Meissner I, Whisnant JP, Kandheria BK, Spittell PC, O’ Fallon WM, Pascoe RD, et al. Prevalence of potential risk factors for stroke assessed by transesophageal and carotid ultrasonography: the SPARC study. Stroke prevention: assessment of risk in a community. Mayo Clin Proc. 1999;74:862-9.
DOI: 10.4065/74.9.862
PMID: 10488786
7. Chen GP, Goldberg SL, Gill EA. Patent foramen ovale and the platypnea-orthodeoxia syndrome. Cardiol Clin. 2005;23(1):85-9.
DOI: 10.1016/j.ccl.2004.10.003
PMID: 15676271
8. Rashkind WJ. Transcatheter treatment of congenital heart disease. Circulation. 1983;67(4):711-6.
DOI: 10.1161/01.CIR.67.4.711
PMID: 6825227
9. Meier B. Closure of patent foramen ovale: technique, pitfalls, complications, and follow up. Heart. 2005;91(4):444-8.
DOI: 10.1136/hrt.2004.052258
PMID: 15772193
10. Messé SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020;94(20):876-85.
DOI: 10.1212/WNL.0000000000009443
PMID: 32350058
11. Leong MC, Uebing A, Gatzoulis MA. Percutaneous patent foramen ovale occlusion: current evidence and evolving clinical practice. Int J Cardiol. 2013;169(4):238-43.
DOI: 10.1016/j.ijcard.2013.08.095
PMID: 24071386
12. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
DOI: 10.1161/01.STR.24.1.35
PMID: 7678184
13. Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke. 2009;40(4):1195-203.
DOI: 10.1161/STROKEAHA.108.529883
PMID: 19246709
14. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al.; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429-38.
DOI: 10.1016/S1474-4422(13)70310-7
PMID: 24646875
15. Pristipino C, Sievert H, D’Ascenzo F, Louis Mas J, Meier B, Scacciatella P, et al.; Evidence Synthesis Team; Eapci Scientific Documents and Initiatives Committee; International Experts. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2019;40(38):3182-95.
DOI: 10.1093/eurheartj/ehy649
PMID: 30358849
16. Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke. 2002;33(3):706-11.
DOI: 10.1161/hs0302.104543
PMID: 11872892
17. Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009;40(7):2349-55.
DOI: 10.1161/STROKEAHA.109.547828
PMID: 19443800
18. Lethen H, Flachskampf FA, Schneider R, Sliwka U, Köhn G, Noth J, et al. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol. 1997;80(8):1066-9.
DOI: 10.1016/S0002-9149(97)00604-8
PMID: 9352979
19. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al.; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991-9.
DOI: 10.1056/NEJMoa1009639
PMID: 22417252
20. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al.; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12):1083-91.
DOI: 10.1056/NEJMoa1211716
PMID: 23514285
21. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al.; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368(12):1092-100.
DOI: 10.1056/NEJMoa1301440
PMID: 23514286
22. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al.; Gore REDUCE Clinical Study Investigators. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033-42.
DOI: 10.1056/NEJMoa1707404
PMID: 28902580
23. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al.; RESPECT Investigators. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022-32.
DOI: 10.1056/NEJMoa1610057
PMID: 28902590
24. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al.; CLOSE Investigators. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011-21.
DOI: 10.1056/NEJMoa1705915
PMID: 28902593
25. Mir H, Siemieniuk RA, Ge L, Foroutan F, Fralick M, Syed T, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open. 2018;8(7):e023761.
DOI: 10.1136/bmjopen-2018-023761
PMID: 30049703
26. De Rosa S, Sievert H, Sabatino J, Polimeni A, Sorrentino S, Indolfi C. Percutaneous closure versus medical treatment in stroke patients with patent foramen ovale: A systematic review and meta-analysis. Ann Intern Med. 2018;168(5):343-50.
DOI: 10.7326/M17-3033
PMID: 29310133
27. Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. Eur Heart J. 2018;39(18):1638-49.
DOI: 10.1093/eurheartj/ehy121
PMID: 29590333
28. Kuijpers T, Spencer FA, Siemieniuk RA, Vandvik PO, Otto CM, Lytvyn L, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ. 2018;362:k2515.
DOI: 10.1136/bmj.k2515
PMID: 30045912
29. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-57.
DOI: 10.1046/j.1526-4610.2001.041007646.x
PMID: 11554952
30. Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lantéri-Minet M, et al. Prevalence and clinical characteristics of migraine in France. Neurology. 2002;59(2):232-7.
DOI: 10.1212/WNL.59.2.232
PMID: 12136063
31. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet. 2000;356(9242):1648-51.
DOI: 10.1016/S0140-6736(00)03160-3
PMID: 11089825
32. Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia. 2008;28(5):531-40.
DOI: 10.1111/j.1468-2982.2008.01554.x
PMID: 18355348
33. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, et al. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation. 2008;117(11):1397-404.
DOI: 10.1161/CIRCULATIONAHA.107.727271
PMID: 18316488
34. Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, et al. Percutaneous closure of patent foramen ovale in patients with migraine: the PREMIUM trial. J Am Coll Cardiol. 2017;70(22):2766-74.
DOI: 10.1016/j.jacc.2017.09.1105
PMID: 29191325
35. Germonpré P. Patent foramen ovale and diving. Cardiol Clin. 2005;23(1):97-104.
DOI: 10.1016/j.ccl.2004.10.005
PMID: 15676273
36. Germonpré P, Dendale P, Unger P, Balestra C. Patent foramen ovale and decompression sickness in sports divers. J Appl Physiol. 1998;84(5):1622-6.
DOI: 10.1152/jappl.1998.84.5.1622
PMID: 9572808
37. Torti SR, Billinger M, Schwerzmann M, Vogel R, Zbinden R, Windecker S, et al. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J. 2004;25(12):1014-20.
DOI: 10.1016/j.ehj.2004.04.028
PMID: 15191771
38. Lairez O, Cournot M, Minville V, Roncalli J, Austruy J, Elbaz M, et al. Risk of neurological decompression sickness in the diver with a right-to-left shunt: literature review and meta-analysis. Clin J Sport Med. 2009;19(3):231-5.
DOI: 10.1097/JSM.0b013e31819b0fa2
PMID: 19423977
39. Billinger M, Zbinden R, Mordasini R, Windecker S, Schwerzmann M, Meier B, et al. Patent foramen ovale closure in recreational divers: effect on decompression illness and ischaemic brain lesions during long-term follow-up. Heart. 2011;97(23):1932-7.
DOI: 10.1136/heartjnl-2011-300436
PMID: 21917666
40. Zaletel M, Koželj M, Podnar T, Peternel P. Odprto ovalno okno. Zdrav Vestn. 2006;75(2):93-100.
41. Rojko M, Černič Šuligoj N, Zorc M, Kar S, Noč M. Perkutano zapiranje odprtega ovalnega okna in okvare medpreddvornega pretina. Zdrav Vestn. 2019;88(11-12):576-81.
42. Zito C, Dattilo G, Oreto G, Di Bella G, Lamari A, Iudicello R, et al. Patent foramen ovale: comparison among diagnostic strategies in cryptogenic stroke and migraine. Echocardiography. 2009;26(5):495-503.
DOI: 10.1111/j.1540-8175.2008.00852.x
PMID: 19452605
43. Silvestry FE, Cohen MS, Armsby LB, Burkule NJ, Fleishman CE, Hijazi ZM, et al.; American Society of Echocardiography; Society for Cardiac Angiography and Interventions. Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. J Am Soc Echocardiogr. 2015;28(8):910-58.
DOI: 10.1016/j.echo.2015.05.015
PMID: 26239900
44. Pizzino F, Khandheria B, Carerj S, Oreto G, Cusmà-Piccione M, Todaro MC, et al. PFO: button me up, but wait … Comprehensive evaluation of the patient. J Cardiol. 2016;67(6):485-92.
DOI: 10.1016/j.jjcc.2016.01.013
PMID: 26917197
45. Rana BS, Thomas MR, Calvert PA, Monaghan MJ, Hildick-Smith D. Echocardiographic evaluation of patent foramen ovale prior to device closure. JACC Cardiovasc Imaging. 2010;3(7):749-60.
DOI: 10.1016/j.jcmg.2010.01.007
PMID: 20633854
46. Kerut EK, Norfleet WT, Plotnick GD, Giles TD. Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol. 2001;38(3):613-23.
DOI: 10.1016/S0735-1097(01)01427-9
PMID: 11527606
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
